TG Therapeutics Inc

TGTX · Moat type: REGULIERUNG

MoatScore

5/10

Fair Value

76 USD

Margin of Safety

+27.3 %

Rating

BEOBACHTEN

TG Therapeutics is a commercial-stage biopharmaceutical company that primarily focuses on the distribution of its MS medication ublituximab (Briumvi) as well as additional hematological and neurological therapeutics, and generates its revenue through prescription growth in these niche preparations.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.